Table 1.
Patient characteristics.
| Factor | Group | post-treatment sIL-2R ≤ UNL (n = 380) | post-treatment sIL-2R > UNL (n = 105) | P value |
|---|---|---|---|---|
| Age | < 65 | 151 (39.7) | 18 (17.1) | < 0.001 |
| ≥ 65 | 229 (60.3) | 87 (82.9) | ||
| B symptoms | Present | 49 (12.9) | 32 (30.5) | < 0.001 |
| Absent | 331 (87.1) | 73 (69.5) | ||
| Bone marrow invasion | Yes | 54 (14.2) | 19 (18.1) | 0.355 |
| No | 326 (85.8) | 86 (81.9) | ||
| COO | GCB | 207 (55.8) | 44 (44.0) | 0.042 |
| Non-GCB | 164 (44.2) | 56 (56.0) | ||
| Extranodal lesions | < 2 | 323 (85.0) | 73 (69.5) | 0.001 |
| ≥ 2 | 57 (15.0) | 32 (30.5) | ||
| IPI | Low/low-int | 298 (78.4) | 60 (57.1) | < 0.001 |
| High/high-int | 82 (21.6) | 45 (42.9) | ||
| PS | 0–1 | 369 (97.1) | 95 (90.5) | 0.006 |
| 2–4 | 11 ( 2.9) | 10 (9.5) | ||
| Pre-treatment sIL-2R | ≤ UNL | 156 (41.1) | 7 (6.7) | < 0.001 |
| > UNL | 224 (58.9) | 98 (93.3) | ||
| Sex | Female | 175 (46.4) | 43 (41.3) | 0.439 |
| Male | 202 (53.6) | 61 (58.7) | ||
| Stage | I, II | 261 (68.7) | 50 (47.6) | < 0.001 |
| III, IV | 119 (31.3) | 55 (52.4) |
COO cell of origin, GCB germinal center B-cell-like type, high-int high-intermediate, IPI international prognostic index, low-int low-intermediate, PS performance status, sIL-2R soluble interleukin-2 receptor, UNL upper normal limit.